Muscular dystrophies at different ages: metabolic and endocrine alterations

Oriana Del Rocío Cruz Guzmán, Ana Laura Chávez García, Maricela Rodríguez-Cruz, Oriana Del Rocío Cruz Guzmán, Ana Laura Chávez García, Maricela Rodríguez-Cruz

Abstract

Common metabolic and endocrine alterations exist across a wide range of muscular dystrophies. Skeletal muscle plays an important role in glucose metabolism and is a major participant in different signaling pathways. Therefore, its damage may lead to different metabolic disruptions. Two of the most important metabolic alterations in muscular dystrophies may be insulin resistance and obesity. However, only insulin resistance has been demonstrated in myotonic dystrophy. In addition, endocrine disturbances such as hypogonadism, low levels of testosterone, and growth hormone have been reported. This eventually will result in consequences such as growth failure and delayed puberty in the case of childhood dystrophies. Other consequences may be reduced male fertility, reduced spermatogenesis, and oligospermia, both in childhood as well as in adult muscular dystrophies. These facts all suggest that there is a need for better comprehension of metabolic and endocrine implications for muscular dystrophies with the purpose of developing improved clinical treatments and/or improvements in the quality of life of patients with dystrophy. Therefore, the aim of this paper is to describe the current knowledge about of metabolic and endocrine alterations in diverse types of dystrophinopathies, which will be divided into two groups: childhood and adult dystrophies which have different age of onset.

Figures

Figure 1
Figure 1
Histology of necrotic skeletal muscle. Image (a) showed a normal skeletal muscle from quadriceps muscle, characterized by healthy myofibres with peripheral nuclei (PN). Skeletal muscle of control subjects was obtained from males without dystrophinopathies at 40 years old. Image (b) showed a necrotic skeletal muscle from quadriceps muscle of a patient with DMD/DMB at five years old, characterized by infiltrating inflammatory cells (ICs) and degenerating myofibres (DMs). Transverse muscle sections stained with haematoxylin and eosin. Scale bar represents 50 m. This biopsy was obtained for the purpose of performing diagnostic.
Figure 2
Figure 2
Side effects of glucocorticoid treatment in muscular dystrophies.
Figure 3
Figure 3
Some aspects of impaired glucose metabolism in patients with childhood muscular dystrophies. The damage in the glucose metabolism, no matter the reason, may probably be one of the causes for energy deficit in DMD patients, and this low energy could result in muscular weakness in muscular dystrophies.
Figure 4
Figure 4
Endocrine abnormalities described in MD1/MD2.

References

    1. Dalkilic I, Kunkel LM. Muscular dystrophies: genes to pathogenesis. Current Opinion in Genetics and Development. 2003;13(3):231–238.
    1. Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle and Nerve. 2001;24(12):1575–1594.
    1. Bushby K. Recent advances in paediatric muscular dystrophies. Current Paediatrics. 2004;14(3):214–222.
    1. Motlagh B, MacDonald JR, Tarnopolsky MA. Nutritional inadequacy in adults with muscular dystrophy. Muscle and Nerve. 2005;31(6):713–718.
    1. Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of duchenne muscular dystrophy. Neuromuscular Disorders. 2011;21(4):298–303.
    1. Smith AG, Muscat GEO. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. International Journal of Biochemistry and Cell Biology. 2005;37(10):2047–2063.
    1. Abdul-Ghani MA, Defronzo RA. Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine and Biotechnology. 2010;2010 Article ID 476279.
    1. Watanabe M, Hayasaki H, Tamayama T, Shimada M. Histologic distribution of insulin and glucagon receptors. Brazilian Journal of Medical and Biological Research. 1998;31(2):243–256.
    1. Borissova AM, Tankova TI, Koev DJ. Insulin secretion, peripheral insulin sensitivity and insulin-receptor binding in subjects with different degrees of obesity. Diabetes and Metabolism. 2004;30(5):425–431.
    1. Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GJB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle and Nerve. 2006;34(2):135–144.
    1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 2010;9(1):77–93.
    1. Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J. The multidisciplinary management of Duchenne muscular dystrophy. Current Paediatrics. 2005;15(4):292–300.
    1. Gonzalez-Bermejo J, Lofaso F, Falaize L, et al. Resting energy expenditure in Duchenne patients using home mechanical ventilation. European Respiratory Journal. 2005;25(4):682–687.
    1. Finsterer J, Stöllberger C. The heart in human dystrophinopathies. Cardiology. 2003;99(1):1–19.
    1. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders. 2002;12(10):926–929.
    1. Koening M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus becker muscular dystrophy: correlation of severity with type of deletion. American Journal of Human Genetics. 1989;45(4):498–506.
    1. Bushby KMD, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. Journal of Neurology. 1993;240:98–104.
    1. Nigro G, Comi LI, Politano L, Bain RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. International Journal of Cardiology. 1990;26(3):271–277.
    1. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. American Journal of Human Genetics. 1991;49(1):54–67.
    1. Nigro G, Comi LI, Politano L, Bain RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. International Journal of Cardiology. 1990;26(3):271–277.
    1. Emery AEH. X-linked muscular dystrophy with early contractures and cardiomyopathy (Emery-Dreifuss type) Clinical Genetics. 1987;32(5):360–367.
    1. Muchir A, Worman HJ. Emery-Dreifuss muscular dystrophy. Current Neurology and Neuroscience Reports. 2007;7(1):78–83.
    1. Rowland LP, Fetell M, Olarte M. Emery-Dreifuss muscular dystrophy. Annals of Neurology. 1979;5(2):111–117.
    1. Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing and Clinical Electrophysiology. 2000;23(11 I):1661–1666.
    1. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nature Reviews Molecular Cell Biology. 2006;7(10):762–773.
    1. Emanuel BS, Zackai EH, Tucker SH. Further evidence for Xp21 location of Duchenne muscular dystrophy (DMD) locus: X;9 translocation in a female with DMD. Journal of Medical Genetics. 1983;20(6):461–463.
    1. Carter GT, Weiss MD, Chamberlain JR, et al. Aging with muscular dystrophy: pathophysiology and clinical management. Physical Medicine and Rehabilitation Clinics of North America. 2010;21(2):429–450.
    1. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345(6273):315–319.
    1. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. The Journal of Biochemistry. 1990;108(5):748–752.
    1. Barton ER. Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. American Journal of Physiology. 2006;290(2):C411–C419.
    1. Bonilla E, Samitt CE, Miranda AF, et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell suface. Cell. 1988;54(4):447–452.
    1. Ren Z, Zhou C, Xu Y, Deng J, Zeng H, Zeng Y. Mutation and haplotype analysis for Duchenne muscular dystrophy by single cell multiple displacement amplification. Molecular Human Reproduction. 2007;13(6):431–436.
    1. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiological Reviews. 2002;82(2):291–329.
    1. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nature Genetics. 1999;21(3):285–288.
    1. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nature Genetics. 1994;8(4):323–327.
    1. Worman HJ, Bonne G. ‘Laminopathies’: a wide spectrum of human diseases. Experimental Cell Research. 2007;313(10):2121–2133.
    1. Wydner KL, McNeil JA, Lin F, Worman HJ, Lawrence JB. Chromosomal assignment of human nuclear envelope protein genes LMNA, LMNB1, and LBR by fluorescence in situ hybridization. Genomics. 1996;32(3):474–478.
    1. Aebi U, Cohn J, Buhle L, Gerace L. The nuclear lamina is a meshwork of intermediate-type filaments. Nature. 1986;323(6088):560–564.
    1. Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Current Opinion in Rheumatology. 2005;17(6):707–713.
    1. Al-Harbi TM, Bainbridge LJ, McQueen MJ, Tarnopolsky MA. Hypogonadism is common in men with myopathies. Journal of Clinical Neuromuscular Disease. 2008;9(4):397–401.
    1. Nagel BHP, Mortier W, Elmlinger M, Wollmann HA, Schmitt K, Ranke MB. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatrica. 1999;88(1):62–65.
    1. Söderpalm AC, Magnusson P, Åhlander AC, et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscular Disorders. 2007;17(11-12):919–928.
    1. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. Journal of Clinical Endocrinology and Metabolism. 1997;82(6):1661–1667.
    1. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Journal of Clinical Endocrinology and Metabolism. 2005;90(3):1502–1510.
    1. Merlini L, Granata C, Ballestrazzi A, et al. Growth hormone evaluation in duchenne muscular dystrophy. The Italian Journal of Neurological Sciences. 1988;9(5):471–475.
    1. Frank GR, Smith RE. Effective growth hormone therapy in a growth hormone deficient patient with Duchenne muscular dystropy without evidence of acceleration of the dystrophic process. Journal of Pediatric Endocrinology and Metabolism. 2001;14(2):211–214.
    1. Leung DG, Germain-Lee EL, Denger BE, Wagner KR. Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA. Neuromuscular Disorders. 2011;21(8):594–601.
    1. McNeil DE, Davis C, Jillapalli D, Targum S, Durmowicz A, Coté TR. Duchenne muscular dystrophy: drug development and regulatory considerations. Muscle and Nerve. 2010;41(6):740–745.
    1. Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB Journal. 2005;19(8):880–891.
    1. Zhou GQ, Xie HQ, Zhang SZ, Yang ZM. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Chinese Medical Journal. 2006;119(16):1381–1391.
    1. Radley HG, De Luca A, Lynch GS, Grounds MD. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. International Journal of Biochemistry and Cell Biology. 2007;39(3):469–477.
    1. Zatz M, Betti RTB, Opitz JM, Reynolds JF. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. American Journal of Medical Genetics. 1981;10(3):301–304.
    1. Griffiths RD, Edwards RHT. A new chart for weight control in Duchenne muscular dystrophy. Archives of Disease in Childhood. 1988;63(10):1256–1258.
    1. Willig TN, Carlier L, Legrand M, Riviere H, Navarro J. Nutritional assessment in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology. 1993;35(12):1074–1082.
    1. Zanardi M, Tagliabue A, Orcesi S, Berardinelli A, Uggetti C, Pichiecchio A. Body composition with dual energy x-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve. 2003;19(6):777–779.
    1. Martigne L, Salleron J, Mayer M, et al. Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. British Journal of Nutrition. 2011;105(10):1486–1491.
    1. Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. Journal of Human Nutrition and Dietetics. 2009;22(5):383–393.
    1. Wolfe RR. Control of muscle protein breakdown: effects of activity and nutritional states. International Journal of Sport Nutrition. 2001;11:S164–S169.
    1. Borrelli O, Salvia G, Mancini V, et al. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. American Journal of Gastroenterology. 2005;100(3):695–702.
    1. Shimizu-Fujiwara M, Komaki H, Nakagawa E, et al. Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain and Development. 2012;34(3):206–212.
    1. Güell MR, Avendano M, Fraser J, Goldstein R. Pulmonary and nonpulmonary alterations in Duchenne muscular dystrophy. Archivos de Bronconeumologia. 2007;43(10):557–561.
    1. Pane M, Vasta I, Messina S, et al. Feeding problems and weight gain in Duchenne muscular dystrophy. European Journal of Paediatric Neurology. 2006;10(5-6):231–236.
    1. Barlow SE, Dietz WH. Obesity evaluation and treatment: expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics. 1998;102(3):p. E29.
    1. Lopez-Jimenez F, Miranda WR. Diagnosing obesity: beyond BMI. American Medical Association Journal of Ethics. 2010;12(4):292–298.
    1. Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand F, Hankard R. Assessing change in body composition in children with Duchenne muscular dystrophy: anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry. Clinical Nutrition. 2010;29(5):633–638.
    1. Kanda F, Fujii Y, Takahashi K, Fujita T. Dual-energy X-ray absorptiometry in neuromuscular diseases. Muscle and Nerve. 1994;17(4):431–435.
    1. Mok E, Béghin L, Gachon P, et al. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. American Journal of Clinical Nutrition. 2006;83(1):65–69.
    1. Drefus J, Schapira G, Schapira F, Demos J. Activites enzymatiques du muscle humain: recherches sur la bichimie comparee de l’homme normal et myopathique et du rat. Clinica Chimica Acta. 1956;1(5):434–449.
    1. Ellis DA. Intermediary metabolism of muscle in Duchenne muscular dystrophy. British Medical Bulletin. 1980;36(2):165–171.
    1. Sharma U, Atri S, Sharma MC, Sarkar C, Jagannathan NR. Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study. Magnetic Resonance Imaging. 2003;21(2):145–153.
    1. Ibrahimi A, Bonen A, Blinn WD, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. Journal of Biological Chemistry. 1999;274(38):26761–26766.
    1. Nishio H, Wada H, Matsuo T, et al. Glucose, free fatty acid and ketone body metabolism in Duchenne muscular dystrophy. Brain and Development. 1990;12(4):390–402.
    1. Freidenberg GR, Olefsky JM. Dissociation of insulin resistance and decreased insulin receptor binding in Duchenne muscular dystrophy. Journal of Clinical Endocrinology and Metabolism. 1985;60(2):320–327.
    1. DeFronzo R, Deibert D, Hendler R. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. Journal of Clinical Investigation. 1979;63(5):939–946.
    1. Mokri B, Engel AG. Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology. 1975;25(12):1111–1120.
    1. Yechiel E, Barenholz Y. Relationships between membrane lipid composition and biological properties of rat myocytes. Journal of Biological Chemistry. 1985;260(16):9123–9131.
    1. Hsieh TJ, Wang CK, Chuang HY, Jong YJ, Li CW, Liu GC. In Vivo proton magnetic resonance spectroscopy assessment for muscle metabolism in neuromuscular diseases. Journal of Pediatrics. 2007;151(3):319–321.
    1. Illa I, Serrano C, Gallardo E, et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology. 2001;49:130–134.
    1. Broglio L, Tentorio M, Cotelli MS, et al. Limb-girdle muscular dystrophy-associated protein diseases. Neurologist. 2010;16(6):340–352.
    1. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. Journal of Neurology, Neurosurgery and Psychiatry. 2009;80(11):1186–1193.
    1. Reilich P, Schramm N, Schoser B, et al. Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy. Journal of Neurology. 2010;257(7):1108–1118.
    1. Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Current Neurology and Neuroscience Reports. 2009;9(1):76–82.
    1. Reilich P, Schramm N, Schoser B, et al. Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy. Journal of Neurology. 2010;257(7):1108–1118.
    1. Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochimica et Biophysica Acta. 2007;1772(2):195–204.
    1. Harper PSH. Myotonic Dystrophy. 3rd edition. London, UK: W.B. Saunders; 2001.
    1. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808.
    1. De Die-Smulders CEM, Höweler CJ, Thijs C, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain. 1998;121(8):1557–1563.
    1. Sicot G, Gourdon F, Gomes M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Human Molecular Genetics. 2011;20(2):116–123.
    1. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Human Molecular Genetics. 2000;9(14):2141–2147.
    1. Rocha CT, Hoffman EP. Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. Current Neurology and Neuroscience Reports. 2010;10(4):267–276.
    1. Antonini G, Clemenzi A, Bucci E, et al. Hypogonadism in DM1 and its relationship to erectile dysfunction. Journal of Neurology. 2011;258(7):1247–1253.
    1. Vazquez JA, Pinies JA, Martul P, De los Rios A, Gatzambide S, Busturia MA. Hypothalamic-pituitary-testicular function in 70 patients with myotonin dystrophy. Journal of Endocrinological Investigation. 1990;13(5):375–379.
    1. Gomez Saez JM, Fernandez Real JM, Fernandez Castaner M, Navarro Moreno MA, Martinez Matos JA, Soler Ramon J. Study on growth hormone and insulin secretion in myotonic dystrophy. Clinical Investigator. 1994;72(7):508–511.
    1. Mastrogiacomo I, Bonanni G, Menegazzo E, et al. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Italian Journal of Neurological Sciences. 1996;17(1):59–65.
    1. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science. 1992;255(5049):1253–1255.
    1. Vazquez JA, Pinies JA, Martul P, De los Rios A, Gatzambide S, Busturia MA. Hypothalamic-pituitary-testicular function in 70 patients with myotonin dystrophy. Journal of Endocrinological Investigation. 1990;13(5):375–379.
    1. Mastrogiacomo I, Bonanni G, Menegazzo E, et al. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Italian Journal of Neurological Sciences. 1996;17(1):59–65.
    1. Griggs RC, Halliday D, Kingston W, Moxley RT. Effect of testosterone on muscle protein synthesis in myotonic dystrophy. Annals of Neurology. 1986;20(5):590–596.
    1. Antonini G, Clemenzi A, Bucci E, et al. Hypogonadism in DM1 and its relationship to erectile dysfunction. Journal of Neurology. 2011;258(7):1247–1253.
    1. Chaudhry V, Umapathi T, Ravich WJ. Neuromuscular diseases and disorders of the alimentary system. Muscle and Nerve. 2002;25(6):768–784.
    1. Matsumura T, Iwahashi H, Funahashi T, et al. A cross-sectional study for glucose intolerance of myotonic dystrophy. Journal of the Neurological Sciences. 2009;276(1-2):60–65.
    1. Kaminsky P, Poussel M, Pruna L, Deibener J, Chenuel B, Brembilla-Perrot B. Organ dysfunction and muscular disability in myotonic dystrophy type 1. Medicine. 2011;90(4):262–268.
    1. Aitkens S, Kilmer DD, Wright NC, McCrory MA. Metabolic syndrome in neuromuscular disease. Archives of Physical Medicine and Rehabilitation. 2005;86(5):1030–1036.
    1. Björntorp P, Rosmond R. The metabolic syndrome—a neuroendocrine disorder? British Journal of Nutrition. 2000;83(1):S49–S57.
    1. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature Genetics. 2001;29(1):40–47.
    1. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology. 1989;3(8):1263–1269.
    1. Walsh JC, Turtle JR, Miller S, Mcleod JG. Abnormalities of insulin secretion in dystrophia myotonica. Brain. 1970;93(4):731–742.
    1. Perseghin G, Caumo A, Arcelloni C, et al. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care. 2003;26(7):2112–2118.
    1. Bertuzzi F, Davalli AM, Nano R, et al. Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes. 1999;48(10):1971–1978.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel